Literature DB >> 8787883

Uptake of azithromycin by various cells and its intracellular activity under in vivo conditions.

A Wildfeuer1, H Laufen, T Zimmermann.   

Abstract

The concentrations of azithromycin in polymorphonuclear leukocytes (PMNLs), monocytes, erythrocytes, and plasma were measured in six healthy volunteers after the last treatment of a 3-day regimen of 500 mg once daily. Marked enrichment of azithromycin was found in PMNLs and monocytes. The drug concentrations after the last dose amounted to 114 +/- 43 (mean +/- standard deviation) mg/liter at 12 h in PMNLs and 34 +/- 17 mg/liter at 6 h in monocytes. Fourteen days thereafter, azithromycin was still detectable in the PMNLs at 53 +/- 34 mg/liter and in the monocytes at 1 +/- 2 mg/liter, although the drug was no longer detectable in plasma (< 0.02 mg/liter). Maximum drug concentrations for azithromycin in plasma (0.40 +/- 0.30 mg/liter) and erythrocytes (0.15 +/- 0.05 mg/liter) at 3 h after the last administration were much lower and occurred earlier than those observed in the phagocytic cells. The mean enrichment factors (cellular/extracellular ratios) of azithromycin in phagocytes relative to plasma came to 231 +/- 150 and 3,924 +/- 584 at 3 and 120 h, respectively, for PMNLs and 83 +/- 55 and 523 +/- 285 at 3 and 120 h for monocytes, respectively, after the last dose. The phagocytosis tests with PMNLs separated from the blood of volunteers at various times after the last treatment confirmed the enhanced intracellular activity of these cells against staphylococci.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8787883      PMCID: PMC163060     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Mechanism of azithromycin uptake in human polymorphonuclear leucocytes.

Authors:  H Laufen; A Wildfeuer; P Lach
Journal:  Arzneimittelforschung       Date:  1990-06

2.  Azithromycin versus cefaclor in the treatment of acute bacterial pneumonia.

Authors:  G Kinasewitz; R G Wood
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

Review 3.  Dynamics of the macrophage plasma membrane.

Authors:  S H Zuckerman; S D Douglas
Journal:  Annu Rev Microbiol       Date:  1979       Impact factor: 15.500

Review 4.  Properties and structural basis of simple diffusion pathways in the erythrocyte membrane.

Authors:  B Deuticke
Journal:  Rev Physiol Biochem Pharmacol       Date:  1977       Impact factor: 5.545

5.  Uptake of antibiotics by human polymorphonuclear leukocyte cytoplasts.

Authors:  W L Hand; N L King-Thompson
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

6.  Distribution of orally administered azithromycin in various blood compartments.

Authors:  A Wildfeuer; H Laufen; T Zimmermann
Journal:  Int J Clin Pharmacol Ther       Date:  1994-07       Impact factor: 1.366

7.  Kinetics of the uptake of antimicrobial agents by human polymorphonuclear leucocytes.

Authors:  H Laufen; A Wildfeuer
Journal:  Arzneimittelforschung       Date:  1989-02

8.  In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection.

Authors:  R P Gladue; G M Bright; R E Isaacson; M F Newborg
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

9.  Uptake of antimicrobial agents by human polymorphonuclear leucocytes.

Authors:  H Laufen; A Wildfeuer; K Räder
Journal:  Arzneimittelforschung       Date:  1985

10.  Membrane transport of clindamycin in alveolar macrophages.

Authors:  W L Hand; N L King-Thompson
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191

View more
  29 in total

1.  Uptake, transport, and delivery of antimicrobial agents by human polymorphonuclear neutrophils.

Authors:  G L Mandell; E Coleman
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Absolute bioavailability and intracellular pharmacokinetics of azithromycin in patients with cystic fibrosis.

Authors:  Paul Beringer; Kitty My Tu Huynh; Jane Kriengkauykiat; Luke Bi; Nils Hoem; Stan Louie; Emily Han; Thao Nguyen; Donald Hsu; Purush A Rao; Bertrand Shapiro; Mark Gill
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

3.  Comparative pharmacokinetics of azithromycin in serum and white blood cells of healthy subjects receiving a single-dose extended-release regimen versus a 3-day immediate-release regimen.

Authors:  Ping Liu; Hameed Allaudeen; Richa Chandra; Kem Phillips; Arvid Jungnik; Jeanne D Breen; Amarnath Sharma
Journal:  Antimicrob Agents Chemother       Date:  2006-10-23       Impact factor: 5.191

Review 4.  The role of advanced generation macrolides in the prophylaxis and treatment of Mycobacterium avium complex (MAC) infections.

Authors:  G W Amsden; C A Peloquin; S E Berning
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

5.  Development of a population pharmacokinetic model to describe azithromycin whole-blood and plasma concentrations over time in healthy subjects.

Authors:  T Pene Dumitrescu; T Anic-Milic; K Oreskovic; J Padovan; K L R Brouwer; P Zuo; V D Schmith
Journal:  Antimicrob Agents Chemother       Date:  2013-04-29       Impact factor: 5.191

6.  Liquid Chromatography Mass Spectrometry Detection of Antibiotic Agents in Sputum from Persons with Cystic Fibrosis.

Authors:  Tara Gallagher; Stefan Riedel; Joseph Kapcia; Lindsay J Caverly; Lisa Carmody; Linda M Kalikin; Junnan Lu; Joann Phan; Matthew Gargus; Miki Kagawa; Simon W Leemans; Jason A Rothman; Felix Grun; John J LiPuma; Katrine L Whiteson
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

7.  Azithromycin versus ciprofloxacin for treatment of uncomplicated typhoid fever in a randomized trial in Egypt that included patients with multidrug resistance.

Authors:  N I Girgis; T Butler; R W Frenck; Y Sultan; F M Brown; D Tribble; R Khakhria
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

8.  Mononuclear and polymorphonuclear leukocyte dispositions of clarithromycin and azithromycin in AIDS patients requiring Mycobacterium avium complex prophylaxis.

Authors:  K Q Bui; J McNabb; C Li; C H Nightingale; D P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

9.  Topical azithromycin and clarithromycin inhibit acute and chronic skin inflammation in sensitized mice, with apparent selectivity for Th2-mediated processes in delayed-type hypersensitivity.

Authors:  Vanesa Ivetić Tkalčević; Snježana Cužić; Miroslava Dominis Kramarić; Michael J Parnham; Vesna Eraković Haber
Journal:  Inflammation       Date:  2012-02       Impact factor: 4.092

10.  Single-dose azithromycin for acute otitis media: a pharmacokinetic/pharmacodynamic rationale.

Authors:  Constance D Rothermel
Journal:  Curr Ther Res Clin Exp       Date:  2003
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.